Êó¿âÈ«Êé
-
-
-
ÃñΪÉúÎïÁ½¿îÈý°Ðµã1ÀàÐÂÒ©»ñµÃÁÙ´²ÊÔÑéĬʾÐí¿É£¡½âËø·ÊÅÖСÊóÄ£ÐÍ·ÇÁÙ´²ÆÀ¼Û²ßÂÔ
2025-01-15½üÈÕ£¬Öйú¹ú¼ÒÒ©¼à¾Ö£¨NMPA£©Ò©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©¹ÙÍø¹«Ê¾£¬ÓÉÃñΪÉúÎïÉ걨µÄ2¿î1ÀàÐÂÒ©MWN109×¢ÉäÒº£¬MWN105×¢ÉäÒº»ñÅúÁÙ´²ÊÔÑ飨IND£©Ðí¿É£¬ÕâÁ½¿îÐÂÒ©¾ùÄ⿪·¢ÖÎÁÆIIÐÍÌÇÄò²¡¡¢³¬ÖØ»òÕß·ÊÅÖ¡£¸ù¾ÝÒѹ«¿ª×ÊÁÏ£¬MWN109×¢ÉäÒº£¬GIP/GLP-1/GCGÈý°ÐµãÖ¬·¾ËáÁ´ÐÞÊζàëÄÒ©ÎMWN105×¢ÉäÒº£¬GIP/GLP-1/FGF21Èý°ÐµãFcÈںϵ°°×Ò©ÎĿǰÁ½¸öÏîÄ¿¶¼´¦ÓÚÒ»ÆÚÁÙ´²½×¶Î¡£
-
-
-
-
¸ß¸ÊÓÍÈýõ¥ÑªÖ¢Ä£Ðͽø½×£º´Ó½ü½»Ïµµ½ ¡°Ò°»¯Êó¡±£¬¿ªÆôѪ֬Ñо¿¶àÔª ¡°Ò°Éú¡± ƪ
2025-01-07¸ß¸ÊÓÍÈýõ¥ÑªÖ¢ÊÇʲô£¿ÓÐÄÄЩΣº¦£¿ÔÚÁÙ´²´úлµÄÑо¿ÖУ¬Ð¡ÊóÄ£Ð͵ÄÓ¦ÓÃÓкξÖÏÞÐÔ£¿Ò°»¯ÊóÓÖÊÇÈçºÎ°ïÖú´ò¿ªÑªÖ¬Ñо¿µÄÐÂÍ»ÆÆ¿ÚµÄ£¿OGÊÓѶ¹ÙÍøÎªÄúÒ»Ò»½â¶Á¡£
-
-
-
-
Ò»¼¶·À¡°ÀÇ¡±¾¯±¨Æô¶¯£¬SLEСÊóÄ£ÐÍÖØ°õ³ö»÷£¡
2025-01-07ϵͳÐÔºì°ßÀÇ´¯£¨SLE£©ÊÇÒ»ÖÖ³£¼ûµÄ×ÔÉíÃâÒßÐÔ¼²²¡£¬Ëü¿ÉÒÔÀÛ¼°È«Éí¼¸ºõËùÓÐµÄÆ÷¹ÙºÍϵͳ£¬ÎÒÃÇ¿´µÃ¼ûµÄÓÐÆ¤·ôÉϵĵûÐκì°ß¡¢ÅÌ×´ºì°ßµÈ±íÏÖ£¬·´¸´µÄ¡¢¶à·¢µÄ¿ÚÇ»À£Ññ£¬ÁîÈË¿àÄÕµÄÍÑ·¢¡£¾Ý±¨µÀ£¬ÖйúµÄSLEÔ¤¹À·¢²¡ÂÊλ¾ÓÈ«ÇòµÚËÄ£¬ÊÇÈ«Çò·¶Î§ÄÚSLE»¼ÕßÈËÊý×î¶àµÄ¹ú¼Ò¡£½üÄêÀ´£¬ÏµÍ³ÐÔºì°ßÀÇ´¯ÓÉÓÚÒ½ÁÆË®Æ½µÄÉÏÉý£¬»¼Õß5ÄêÉú´æÂʲ»¶ÏÌá¸ß£¬µ«²¡ËÀÂÊÈԽϸߡ£ÎªÁ˸ÄÉÆÕâÒ»ÏÖ×´£¬Ïà¹ØÒ©ÎïµÄ¿ª·¢´Óδֹ²½¡£sleСÊóÄ£ÐͳÉΪÐÂÒ©¿ª·¢µÄÖØÒªÒ»»·¡£
-
-
-
-
MHCÈËÔ´»¯Ð¡ÊóÓ¦Óö࣡ÓÐÍû³ÉΪÃâÒßÖÎÁÆÐ¡°¶¥Á÷¡±
2025-01-07MHCÒò×ÓÊÇʲô£¿ËüÔÚÃâÒßÖÎÁÆÖеŦÄÜÓÐÄÄЩ£¿MHCÈËÔ´»¯Ð¡ÊóÓÖÊÇÈçºÎ·¢»Ó×÷Óõģ¿OGÊÓѶ¹ÙÍø´øÄã¿´¡£
-
-
-
-
NeoMab?È«ÈË¿¹Ìå·¢ÏÖÆ½Ì¨£º»ùÓÚÈ«ÈËÔ´¿¹Ìåת»ùÒòСÊóÒýÁ쿹Ì忪·¢
2025-01-03ÖÎÁÆÐÔ¿¹ÌåÔÚҽѧÁìÓò°çÑÝ׏ؼüµÄ½ÇÉ«£¬²»½ö±»¹ã·ºÓÃÓÚÖÎÁư©Ö¢¡¢×ÔÉíÃâÒßÐÔ¼²²¡ºÍ´«È¾ÐÔ¼²²¡µÈ¶àÖÖ¼²²¡£¬»¹ÔÚһЩÐÂÐ˵ÄÉúÎïÁÆ·¨Öз¢¹â·¢ÈÈ¡£¡£È»¶ø£¬´«Í³µÄ¿¹Ìå·¢ÏÖ·½·¨ÔÚ¿ª·¢ÖÜÆÚ¡¢ÃâÒßÔÐÔ¡¢Îȶ¨ÐÔºÍÌØÒìÐԵȷ½Ãæ´æÔÚÌôÕ½¡£OGÊÓѶ¹ÙÍø»ùÓÚNeoMab?¿¹ÌåÈ«ÈËԴת»ùÒòСÊ󣬳ÉÁ¢ÁËרעÓÚÈ«ÈË¿¹Ì忪·¢µÄ·Ö¹«Ë¾Å¦ÂõÉúÎ²¢½¨Á¢ÁËNeoMab?È«ÈË¿¹Ìå·¢ÏÖÆ½Ì¨£¬ÎªÖÂÁ¦ÓÚ¿¹ÌåÑз¢µÄÑо¿»ú¹¹£¬ÉúÎï¼¼Êõ¹«Ë¾ºÍÖÆÒ©ÆóÒµÌṩ¸üÁé*»î¡¢¸ü¾ßÐԼ۱ȵĽâ¾ö·½°¸¡£
-
-
-
-
OGÊÓѶ¹ÙÍøÓë¶à·½ÁªÊÖÑо¿£¬ÎªÃâÒßÖ×ÁöѧÑо¿ÌṩÈËÔ´»¯Ð¡ÊóÄ£ÐÍÓÅÑ¡²ßÂÔ
2025-01-02½üÈÕ£¬Éñ¾ÓëÖ×ÁöÒ©ÎïÑз¢È«¹úÖØµãʵÑéÊÒ¡¢ÏÈÉùÔÙÃ÷¡¢ÏÈÉùÒ©Òµ¡¢OGÊÓѶ¹ÙÍøµÈ»ú¹¹µÄרҵÑо¿ÈËÔ±¹²Í¬ºÏ×÷ÔÚ¡¶International Immunopharmacology¡·ÉÏ·¢±íÌâΪTechnical considerations and strategies for generating and optimizing humanized mouse tumor models in immuno-oncology research[1]µÄÑо¿ÂÛÎÄ¡£ÂÛÎÄÖ¼ÔÚ½¨Á¢¡¢ÓÅ»¯¶àÖÖÓÃÓÚÃâÒßÖ×Áöѧ£¨IO£©Ñо¿µÄÃâÒßÖØ½¨£¨HIS£©Ä£ÐÍ£¬ÎªÉè¼Æ¡¢Éú³É¡¢Ê¹ÓúÏÊʵÄHISÄ£ÐÍÒÔ½â¾öת»¯IOÖеÄÌØ¶¨ÎÊÌâÌṩÁ˱¦¹óµÄ·½·¨ºÍ¿ÉÐеļ¼ÊõÖ¸µ¼¡£À´×ÔOGÊÓѶ¹ÙÍø×ÔÖ÷²úȨµÄBALB/c-hTNFR2 KI»ùÒòÈËÔ´»¯Ð¡ÊóºÍCT26-hTNFR2 KIϸ°ûϵÔÚÑо¿Öз¢»ÓÁËÖØÒª×÷Óá£
-
